Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A (Amibegron) in Elderly Patients with Generalized Anxiety Disorder
NCT00535340Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Mar 2007
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of amibegron in generalized anxiety disorder (GAD), sponsored by Sanofi. Started Mar 2007; status: terminated.
02
Drugs
amibegron
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00535340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00535340.